LEO Pharma Completes Peplin Inc. Acquisition; Peplin to Continue as an Independent Subsidiary
11/12/2009 11:16:22 AM
EMERYVILLE, Calif. & BRISBANE, Queensland--(BUSINESS WIRE)--Peplin, Inc. (ASX:PLI) today announced that it has completed its merger with LEO Pharma A/S (LEO) after obtaining the approval of the majority of Peplin stockholders. The deal was originally announced on 3 September, 2009 when LEO, a privately-held, leading global pharmaceutical company within Dermatology and Critical Care, agreed to acquire all outstanding securities of Peplin for approximately US$287.5 million in cash. The merger consideration will be distributed to holders of common stock and CDIs promptly.
comments powered by